One-off PSA test may do more harm than good, largest study to date shows

It detects more early-stage, low-grade cancers but makes no difference to mortality
PSA

The largest prostate cancer screening study to date has found that a one-off test detects more early-stage, low-grade cancers but fails to make any difference to mortality.

In the UK study of more than 400,000 general practice patients, about 190,000 men aged 50-69 were invited to have a PSA test. A control group received usual care, meaning no PSA testing if asymptomatic.